Skip to main content

How do your AAV patients present?

Ears and auditory4,5

GPA>MPA

Hearing loss, ear ache

Eyes4, 5

GPA>>MPA

Red, painful eyes

Nose and sinuses2,4,5

GPA>>MPA

Saddle nose deformity,
nasal septum deformity,
sinusitis

Skin2,5

GPA>MPA

Rashes, purpura, lesions

Lungs and upper airways2,4–6

GPA>MPA

Coughing, pain, lung
nodules (seen in X rays),
alveolar haemorrhage

Nervous system2,4,5

CNS (GPA=MPA), PNS
(MPA>GPA)

Mononeuritis,
paraesthesia, other
peripheral neuropathy

Kidneys4,5

MPA>GPA

Blood in the urine

QoL impairment7

Similar to other chronic diseases and includes anxiety, fatigue, sleep disturbance, depression and pain

Ears and auditory4,5

GPA>MPA

Hearing loss, ear ache

Eyes4, 5

GPA>>MPA

Red, painful eyes

Nose and sinuses2,4,5

GPA>>MPA

Saddle nose deformity,
nasal septum deformity,
sinusitis

Skin2,5

GPA>MPA

Rashes, purpura, lesions

Lungs and upper airways2,4–6

GPA>MPA

Coughing, pain, lung
nodules (seen in X rays),
alveolar haemorrhage

Nervous system2,4,5

CNS (GPA=MPA), PNS
(MPA>GPA)

Mononeuritis,
paraesthesia, other
peripheral neuropathy

Kidneys4,5

MPA>GPA

Blood in the urine

QoL impairment7

Similar to other chronic diseases and includes anxiety, fatigue, sleep disturbance, depression and pain

There is a need for a new and more targeted approach to AAV (GPA/MPA) treatment8–11

AAV (GPA/MPA) is a severe, relapsing disease that can cause irreversible damage to multiple organs1-3

Despite treatment, many AAV patients do not achieve or sustain remission and the risk of relapse persists, further exacerbating organ damage12–14

Established therapies for AAV (GPA/MPA) have relied on non-specic immunosuppressants alongside
high-dose and/or long-term GCs, which add to the burden of disease11,14–18

Activation of the alternative complement pathway plays a key role in AAV and no established therapies address this key driver of vascular inflammation9,11,19

Efficacy

See how AAV impacts your patients  
and to hear real life  
patient experiences

VISIT SEE ME HEAR ME

For more information on the  
burden of AAV and the  
mechanism of disease

VISIT UNDERSTAND AAV
Efficacy

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; CNS, central nervous system; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis; PNS, peripheral nervous system; QoL, quality of life.

1. Wallace ZS, Miloslavsky EM. BMJ 2020;368:m421. 2. Pagnoux C. Eur J Rheumatol 2016;3(3):122–33. 3. Al Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34. 4. Hunter RW, et al. BMJ 2020;369:m1070. 5. Kitching AR, et al. Nat Rev Dis Primers 2020;6(1):71. 6. Quartuccio L, et al. J Autoimmun 2020;108:102397. 7. Basu N, et al. Ann Rheum Dis 2014;73(1):207–11. 8. Hutton HL, et al. Semin Nephrol 2017;37(5):418–35. 9. Jennette JC, Nachman PH. Clin J Am Soc Nephrol 2017;12(10):1680–91. 10. Bekker P, et al. PLoS One 2016;11(10):e0164646. 11. Lamprecht P, et al. EMJ Rheumatol 2021;8(1):36–42. 12. Stone JH, et al. N Engl J Med 2010;363(3):221–32. 13. Specks U, et al. N Engl J Med 2013;369(5):417–27. 14. Robson J, et al. Rheumatology (Oxford) 2015;54(3):471–81. 15. Yates M, et al. Ann Rheum Dis 2016;75(9):1583–94. 16. Little MA, et al. Ann Rheum Dis 2010;69(6):1036–43. 17. McGregor JG, et al. Clin J Am Nephrol 2012;7(2):240–7. 18. Turnbull J, Harper L. Best Pract Res Clin Rheumatol 2009;23(3):391–401. 19. Liberman AC, et al. Front Endocrinol (Lausanne) 2018;9:235